Results 21 to 30 of about 14,494 (232)

P-512. Changes in Renal Function After Switching from Emtricitabine/Tenofovir Disoproxil Fumarate to Emtricitabine/Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis (PrEP): A Real-World Study [PDF]

Open Forum Infect Dis
Background In the DISCOVER study (NCT02842086), emtricitabine/tenofovir alafenamide fumarate (F/TAF) showed a more favorable renal safety profile compared with emtricitabine/tenofovir disoproxil fumarate (F/TDF).
Kaori Ito, Xiwen Huang, Seojin Park, Li Tao, J. Gruber   +4 more
europepmc   +2 more sources

Effects of tenofovir alafenamide fumarate on serum lipid profiles in patients with chronic hepatitis B. [PDF]

Virol J
Concerns have been raised regarding changes in lipid profiles among patients with chronic hepatitis B (CHB) during tenofovir alafenamide fumarate (TAF) treatment. We aimed to evaluate the effect of TAF treatment on the lipid profiles of patients with CHB.
Cao F, Fan T, Jiang X, Wang J, Liu Y, Zhu L, Xiong Y, Zhang S, Zhang Z, Pan Y, Li Y, Jiang C, Xia J, Yan X, Li J, Liu X, Zhu C, Huang R, Wu C.   +18 more
europepmc   +2 more sources

Changes in Glomerular Filtration Rate After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Fumarate for Human Immunodeficiency Virus Preexposure Prophylaxis. [PDF]

Open Forum Infect Dis, 2023
Background Tenofovir alafenamide fumarate (TAF) was promoted as a safer alternative to tenofovir disoproxil fumarate (TDF) for human immunodeficiency virus oral preexposure prophylaxis (PrEP).
Rivera AS, Pak K, Mefford MT, Hechter RC.   +3 more
europepmc   +2 more sources

Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort. [PDF]

Viruses, 2023
Background: Bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) is a recommended once-daily single-tablet regimen for the treatment of people living with HIV (PLWH).
Lazzaro A, Bianchini D, Gentilini Cacciola E, Mezzaroma I, Falciano M, Andreoni C, Fimiani C, Santinelli L, Maddaloni L, Bugani G, Ceccarelli G, Mastroianni CM, d'Ettorre G.   +12 more
europepmc   +2 more sources

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide [PDF]

EBioMedicine, 2016
Background: Initiation of antiretroviral therapy (ART) and subsequent virologic suppression reduces immune activation and systemic inflammation. Methods: We examined longitudinal changes in biomarkers of monocyte activation (sCD14, sCD163), and systemic (
Nicholas T. Funderburg, Grace A. McComsey, Manjusha Kulkarni, Tammy Bannerman, Jessica Mantini, Bernadette Thornton, Hui C. Liu, Yafeng Zhang, Qinghua Song, Liang Fang, Jason Dinoso, Andrew Cheng, Scott McCallister, Marshall W. Fordyce, Moupali Das   +14 more
doaj   +3 more sources

Interspecies Differences in Tenofovir Alafenamide Fumarate Stability in Plasma. [PDF]

Antimicrob Agents Chemother, 2020
Tenofovir (TFV) alafenamide fumarate (TAF) is an antiretroviral that has been evaluated in alternative drug delivery systems in several species. The ex vivo stability of TAF was evaluated, and TAF was stable in dog-, sheep-, and macaque-spiked plasma.
Parsons TL, Gwenden KN, Marzinke MA.
europepmc   +4 more sources

Effect of Tenofovir Alafenamide Fumarate on the outcomes of hospitalized COVID-19 patients: a prospective, block-balanced, open-label, randomized controlled trial. [PDF]

BMC Pharmacol Toxicol
The global effort to cure COVID-19 is still ongoing. Thus, a prospective, block-balanced, open-label, randomized controlled trial was conducted to evaluate how Tenofovir Alafenamide Fumarate affects hospitalized COVID-19 patients’ outcomes.
Yazdan Pouri N, Shokati Eshkiki Z, Talebi A, Cheraghian B, Ahmadi F, Neisi N, Shayesteh AA.   +6 more
europepmc   +2 more sources

Relationship between adherence to bictegravir/emtricitabine/tenofovir alafenamide fumarate and clinical outcomes in people with HIV in Japan: a claims database analysis. [PDF]

Sci Rep
A lack of adherence to long-term antiretroviral therapy may impact viral suppression. The current study examined the relationship between medication adherence and clinical outcomes in people with human immunodeficiency virus infection (PWH) receiving ...
Taguchi N, Piao Y, Rubino A, Lee K, Chen M, Harada K, Tanikawa T, Naito T.   +7 more
europepmc   +2 more sources

First year real life experience with tenofovir alafenamide fumarate: The pythagorean cohort. [PDF]

Hepatol Forum, 2023
Background and Aim In chronic hepatitis B infection, antiviral therapy significantly reduces the incidence of complications. This study aimed to present real-life 12-month effectiveness and safety data for TAF.
Karasahin O, Kalkan IA, Dal T, Toplu SA, Harputluoglu M, Mete AO, Komur S, Sarigul F, Yildiz Y, Esmer F, Kandemir O, Nazik S, Inan D, Akgul F, Kaya S, Tunc N, Bayindir Y, Balin SO, Tasova Y, Aktar F, Oner MM, Ayhan M, Demir Y, Celen MK.   +23 more
europepmc   +2 more sources

Assessment of risk factors for virological nonsuppression following switch to dolutegravir and lamivudine, or bictegravir, emtricitabine, and tenofovir alafenamide fumarate in a real-world cohort of treatment-experienced adults living with HIV. [PDF]

PLoS One
Conflicting data exists regarding the baseline determinants of virological nonsuppression outcomes in treatment-experienced people living with human immunodeficiency virus (PWH) switching to antiretroviral treatment (ART) with bictegravir/emtricitabine ...
Lee SY, Lin YC, Chen CP, Cheng SH, Chang SY, Ku SY, Cheng CY.   +6 more
europepmc   +2 more sources